drugset / Trial / NCT03120936
The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community
Phase 4
Completed
158 enrolled
Public Health Foundation Enterprises, Inc.
California HIV/AIDS Research Program · collabSan Francisco Community Health Center · collabSan Francisco Department of Public Health · collabTri-City Health Center · collabUniversity of California, San Francisco · collab
NaSingle-groupOpen-labelOther
Summary
The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be provided Truvada to take orally once daily as PrEP.
Timeline
- Start
- 2017-08-08
- Primary completion
- 2020-08-27
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |
| Subject | emtricitabine | Other / unclassified | 200 mg | Oral |
Indications
No indication recorded.